Microbot Medical Inc. MBOT
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
21.18
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$13.1M | — | -$13.1M | $77.6M |
| 2024 | — | -$11.4M | — | -$8.9M | $3.5M |
| 2023 | — | -$10.7M | — | -$8.6M | $4.5M |
| 2022 | — | -$13.2M | — | -$11.6M | $7.3M |
| 2021 | — | -$11.3M | — | -$9.4M | $14.4M |
| 2020 | — | -$9.2M | — | -$7.3M | $24.3M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 21.18 (safe)
- Working capital / assets 0.937
- Retained earnings / assets -1.276
- EBIT / assets -0.181
- Equity / liabilities 19.437
Source: SEC EDGAR filings · CIK 0000883975 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.